Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic

Journal of Managed Care Pharmacy

Volumn 15, Issue 7, 2009, Pages 563-567

  McFarland, M Shawn ^a,d   Cross, L Brian ^a   Gross, Benjamin ^a   Gentry, Chad ^a   Tunney, Jeffrey ^b   Patel, U P ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b Tennessee Valley Healthcare System   (United States)

^c Murfreesboro Medical Clinic   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SITAGLIPTIN; ANTIDIABETIC AGENT; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG SCREENING; DRUG USE; ELECTRONIC MEDICAL RECORD; FISHER EXACT TEST; GLOMERULUS FILTRATION RATE; HOSPITAL DEPARTMENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NURSE PRACTITIONER; PHARMACIST; PHYSICIAN; PHYSICIAN ASSISTANT; PRESCRIPTION; PREVALENCE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; COHORT ANALYSIS; DOSE RESPONSE; DRUG MONITORING; FACTUAL DATABASE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MEDICATION ERROR; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZATION AND MANAGEMENT; OUTPATIENT DEPARTMENT; PROFESSIONAL STANDARD; STATISTICS; UNITED STATES;

AMBULATORY CARE FACILITIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG UTILIZATION REVIEW; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FUNCTION TESTS; MEDICATION ERRORS; PHARMACISTS; PRIVATE SECTOR; PROFESSIONAL ROLE; PYRAZINES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TRIAZOLES; UNITED STATES;

EID: 70349921996     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.7.563     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008. http://www.cdc.gov/diabetes/pubs/pdf/ndfs- 2007.pdf. Accessed August 13, 2008.
2. Nathan, D. Finding new treatments for diabetes - how many, how fast . . . how good? N Engl J Med. 2007;356(5):437-440 (Pubitemid 46193068)
3. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571
4. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-37. Available at: http://care.diabetesjournals.org/content/29/12/2632.full.pdf+html. Accessed August 10, 2009. (Pubitemid 44912190)
5. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643 (Pubitemid 44912191)
6. Hermansen K, Kipnes M, Luo E et al. Efficacy and safety of the dipeptidyl peptidae-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733-745 (Pubitemid 47261855)
7. Merck & Co. Januvia (sitagliptin) package insert. Whitehouse Station, NJ; 2007. Available at: http://www.merck.com/product/usa/pi-circulars/j/ januvia/januvia-pi.pdf. Accessed August 10, 2009.
8. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28(1):55-72. (Pubitemid 43254990)
9. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675-88. (Pubitemid 41773643)
10. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46(8):876-886 (Pubitemid 44050824)
11. Vincent SH, Reed JR, Bergman, AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos. 2007;35(4):533-38. Available at: http://dmd.aspetjournals.org/cgi/reprint/35/4/ 533. Accessed August 10, 2009.
12. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30(7):1862-1864 (Pubitemid 47036366)
13. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545-555 (Pubitemid 351850898)
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
15. Rigalleau V, Lasseur C, Perlemoine C, et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study? Diabetes Care. 2005;28(4):838-43. Available at: http://care.diabetesjournals.org/content/28/4/838.full.pdf+html. Accessed August 10, 2009. (Pubitemid 40434482)
16. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a concensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203. Available at: http://care.diabetesjournals.org/ content/32/1/193.full.pdf+html. Accessed August 10, 2009.
17. DiGregorio R, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy. 2009;29(3):352-356
18. Golik M, Lawrence K. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and Modification of Diet in Renal Disease. Pharmacotherapy. 2008;28(9):1125-1132
19. Shord S, Bressler L, Radhakrishnan L, Ningyu Chen, Villano J. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose. Ann Pharmacother. 2009;43(2):235-241
20. Hermsen ED, Maiefski M, Florescu MC, Qiu F, Rupp ME. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials. Pharmacotherapy. 2009;29(6):649-655